|
JOP20080381B1
(ar)
*
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
|
US20130072665A1
(en)
*
|
2007-08-23 |
2013-03-21 |
Simon Mark Jackson |
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
|
|
US20130064834A1
(en)
*
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
|
TWI507525B
(zh)
*
|
2009-06-26 |
2015-11-11 |
Regeneron Pharma |
具天然免疫球蛋白形式之易分離的雙專一性抗體
|
|
DK3241435T3
(da)
|
2009-07-08 |
2021-08-23 |
Kymab Ltd |
Dyremodeller og terapeutiske molekyler
|
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
US8518405B2
(en)
|
2009-10-08 |
2013-08-27 |
The University Of North Carolina At Charlotte |
Tumor specific antibodies and uses therefor
|
|
AU2010313324A1
(en)
*
|
2009-10-30 |
2012-04-12 |
Merck Sharp & Dohme Corp. |
AX213 and AX132 PCSK9 antagonists and variants
|
|
AR079336A1
(es)
*
|
2009-12-11 |
2012-01-18 |
Irm Llc |
Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
|
|
JO3274B1
(ar)
|
2009-12-24 |
2018-09-16 |
Regeneron Pharma |
أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
|
|
NZ602220A
(en)
*
|
2010-03-11 |
2014-10-31 |
Rinat Neuroscience Corp |
Antibodies with ph dependent antigen binding
|
|
ES2667100T3
(es)
*
|
2010-08-02 |
2018-05-09 |
Macrogenics, Inc. |
Diacuerpos covalentes y sus usos
|
|
US9845362B2
(en)
|
2010-10-08 |
2017-12-19 |
The University Of North Carolina At Charlotte |
Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
|
|
JO3756B1
(ar)
|
2010-11-23 |
2021-01-31 |
Regeneron Pharma |
اجسام مضادة بشرية لمستقبلات الجلوكاجون
|
|
CN103261230A
(zh)
*
|
2010-12-22 |
2013-08-21 |
霍夫曼-拉罗奇有限公司 |
抗pcsk9抗体及使用方法
|
|
CA2825778A1
(en)
*
|
2011-01-28 |
2012-08-02 |
Sanofi |
Pharmaceutical compositions comprising human antibodies to pcsk9
|
|
EP2650016A1
(en)
|
2011-01-28 |
2013-10-16 |
Sanofi |
Human antibodies to PSCK9 for use in methods of treatment based on particular dosage regimens (11565)
|
|
EP2481758A1
(en)
|
2011-01-28 |
2012-08-01 |
Sanofi |
Human antibodies to PSCK9 for use in methods of treating particular groups of subjects (11566)
|
|
SG10201609665PA
(en)
|
2011-02-25 |
2017-01-27 |
Chugai Pharmaceutical Co Ltd |
FcɣRIIb-SPECIFIC Fc ANTIBODY
|
|
US8337530B2
(en)
|
2011-03-09 |
2012-12-25 |
Zimmer Spine, Inc. |
Polyaxial pedicle screw with increased angulation
|
|
AR088782A1
(es)
|
2011-04-29 |
2014-07-10 |
Sanofi Sa |
Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes
|
|
JOP20200043A1
(ar)
*
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
|
AU2012267732A1
(en)
|
2011-06-10 |
2014-01-09 |
Medimmune Limited |
Anti-Pseudomonas Psl binding molecules and uses thereof
|
|
AR087329A1
(es)
|
2011-06-17 |
2014-03-19 |
Regeneron Pharma |
Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
|
|
WO2013002362A1
(ja)
|
2011-06-30 |
2013-01-03 |
中外製薬株式会社 |
ヘテロ二量化ポリペプチド
|
|
WO2013008185A1
(en)
*
|
2011-07-14 |
2013-01-17 |
Pfizer Inc. |
Treatment with anti-pcsk9 antibodies
|
|
AR087305A1
(es)
*
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
|
ES2773111T3
(es)
|
2011-09-16 |
2020-07-09 |
Regeneron Pharma |
Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a)
|
|
AR087715A1
(es)
|
2011-09-16 |
2014-04-09 |
Lilly Co Eli |
Anticuerpos anti pcsk9 y usos de los mismos
|
|
AU2012311286B2
(en)
*
|
2011-09-19 |
2018-07-26 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
|
WO2013045916A1
(en)
|
2011-09-26 |
2013-04-04 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
|
JP6322411B2
(ja)
|
2011-09-30 |
2018-05-09 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
|
ITPC20110013U1
(it)
|
2011-10-07 |
2013-04-08 |
Giovanni Merli |
Struttura di protezione superiore veicoli.
|
|
WO2013070615A1
(en)
|
2011-11-07 |
2013-05-16 |
Medlmmune, Llc. |
Combination therapies using anti- pseudomonas psl and pcrv binding molecules
|
|
KR20210074395A
(ko)
|
2011-11-30 |
2021-06-21 |
추가이 세이야쿠 가부시키가이샤 |
면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
|
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
WO2013086443A1
(en)
|
2011-12-08 |
2013-06-13 |
Amgen Inc. |
Agonistic human lcat antigen binding proteins and their use in therapy
|
|
KR102063028B1
(ko)
|
2012-01-23 |
2020-01-07 |
리제너론 파아마슈티컬스, 인크. |
항-ａｎｇ2 항체를 함유하는 안정화된 제형
|
|
ES2886123T3
(es)
*
|
2012-01-31 |
2021-12-16 |
Regeneron Pharma |
Anticuerpos anti-asic1 y usos de los mismos
|
|
CA2865158C
(en)
|
2012-02-24 |
2022-11-01 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib
|
|
US9801362B2
(en)
|
2012-03-16 |
2017-10-31 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals expressing pH-sensitive immunoglobulin sequences
|
|
WO2013138681A1
(en)
|
2012-03-16 |
2013-09-19 |
Regeneron Pharmaceuticals, Inc. |
Mice that produce antigen-binding proteins with ph-dependent binding characteristics
|
|
HUE037659T2
(hu)
|
2012-03-16 |
2018-09-28 |
Regeneron Pharma |
Hisztidinmódosított könnyûlánc antitestek és genetikailag módosított rágcsálók ennek az elõállítására
|
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
|
US20130281355A1
(en)
*
|
2012-04-24 |
2013-10-24 |
Genentech, Inc. |
Cell culture compositions and methods for polypeptide production
|
|
EA039663B1
(ru)
*
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
|
|
US9255154B2
(en)
*
|
2012-05-08 |
2016-02-09 |
Alderbio Holdings, Llc |
Anti-PCSK9 antibodies and use thereof
|
|
AR091462A1
(es)
|
2012-06-15 |
2015-02-04 |
Genentech Inc |
Anticuerpos anti-pcsk9, formulaciones, dosificacion y metodos de uso
|
|
NZ704771A
(en)
*
|
2012-08-13 |
2018-02-23 |
Regeneron Pharma |
Anti-pcsk9 antibodies with ph-dependent binding characteristics
|
|
JO3462B1
(ar)
|
2012-08-22 |
2020-07-05 |
Regeneron Pharma |
أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
|
|
TWI855488B
(zh)
|
2012-08-24 |
2024-09-11 |
日商中外製藥股份有限公司 |
FcγRIIb特異性Fc區域變異體
|
|
EP2703009A1
(en)
|
2012-08-31 |
2014-03-05 |
Sanofi |
Combination treatments involving antibodies to human PCSK9
|
|
EP2703008A1
(en)
|
2012-08-31 |
2014-03-05 |
Sanofi |
Human antibodies to PCSK9 for use in methods of treating particular groups of subjects
|
|
EP2706070A1
(en)
|
2012-09-06 |
2014-03-12 |
Sanofi |
Combination treatments involving antibodies to human PCSK9
|
|
JP2015535464A
(ja)
|
2012-11-21 |
2015-12-14 |
アムジエン・インコーポレーテツド |
薬剤送達装置
|
|
CN105102618B
(zh)
|
2012-12-27 |
2018-04-17 |
中外制药株式会社 |
异源二聚化多肽
|
|
US20150335615A1
(en)
*
|
2013-01-04 |
2015-11-26 |
Toshihisa Kawai |
Cholesterol-lowering compounds in combination with lipid metabolism-altering compounds of non-absorbable sugars, compounds that convert nh3 to nh4+, or hydrogen-generating compounds for the treatment of high cholesterol and inflammation
|
|
WO2014107739A1
(en)
*
|
2013-01-07 |
2014-07-10 |
Eleven Biotherapeutics, Inc. |
Antibodies against pcsk9
|
|
US10092703B2
(en)
|
2013-03-15 |
2018-10-09 |
Amgen Inc. |
Drug cassette, autoinjector, and autoinjector system
|
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
|
TWI592183B
(zh)
|
2013-03-15 |
2017-07-21 |
安美基公司 |
本體輪廓可調適之自動注射器裝置
|
|
AU2014235430A1
(en)
*
|
2013-03-15 |
2015-09-24 |
Amgen Inc. |
Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 (PCSK9)
|
|
US10492990B2
(en)
|
2013-03-15 |
2019-12-03 |
Amgen Inc. |
Drug cassette, autoinjector, and autoinjector system
|
|
WO2014149699A1
(en)
|
2013-03-15 |
2014-09-25 |
Eli Lilly And Company |
Bifunctional protein
|
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
ES2853748T3
(es)
|
2013-03-22 |
2021-09-17 |
Amgen Inc |
Inyector y método de montaje
|
|
SG11201508170TA
(en)
|
2013-04-02 |
2015-11-27 |
Chugai Pharmaceutical Co Ltd |
Fc REGION VARIANT
|
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
|
US10111953B2
(en)
*
|
2013-05-30 |
2018-10-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
|
|
TWI682780B
(zh)
*
|
2013-05-30 |
2020-01-21 |
美商再生元醫藥公司 |
醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
|
|
EP2810955A1
(en)
|
2013-06-07 |
2014-12-10 |
Sanofi |
Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
|
|
EP2862877A1
(en)
|
2013-10-18 |
2015-04-22 |
Sanofi |
Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
|
|
TW201534324A
(zh)
|
2013-06-07 |
2015-09-16 |
Sanofi Sa |
藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
|
|
ES2901400T3
(es)
*
|
2013-06-07 |
2022-03-22 |
Regeneron Pharma |
Métodos para inhibir la ateroesclerosis administrando un inhibidor de PCSK9
|
|
JP6267792B2
(ja)
|
2013-06-28 |
2018-01-24 |
アムジエン・インコーポレーテツド |
ホモ接合性家族性高コレステロール血症の治療方法
|
|
WO2015049517A2
(en)
|
2013-10-01 |
2015-04-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
MX373298B
(es)
|
2013-10-11 |
2020-05-20 |
Sanofi Biotechnology |
Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
|
|
MX2016005315A
(es)
|
2013-10-24 |
2016-08-11 |
Amgen Inc |
Sistema de administracion de farmacos con control sensible a la temperatura.
|
|
EP3060275B1
(en)
|
2013-10-24 |
2019-07-03 |
Amgen Inc. |
Injector and method of assembly
|
|
ES2864350T3
(es)
*
|
2013-11-12 |
2021-10-13 |
Regeneron Pharma |
Pautas posológicas para uso con inhibidores de PCSK9
|
|
US10428157B2
(en)
*
|
2013-11-12 |
2019-10-01 |
Sanofi Biotechnology |
Dosing regimens for use with PCSK9 inhibitors
|
|
US9045545B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision medicine by targeting PD-L1 variants for treatment of cancer
|
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
|
US8986694B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Targeting human nav1.7 variants for treatment of pain
|
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
EP3572425A1
(en)
*
|
2013-12-17 |
2019-11-27 |
AIMM Therapeutics B.V. |
Means and methods for counteracting myeloproliferative or lymphoproliferative disorders
|
|
US9023359B1
(en)
|
2014-07-15 |
2015-05-05 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US8992927B1
(en)
|
2014-07-15 |
2015-03-31 |
Kymab Limited |
Targeting human NAV1.7 variants for treatment of pain
|
|
US9051378B1
(en)
|
2014-07-15 |
2015-06-09 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9034332B1
(en)
|
2014-07-15 |
2015-05-19 |
Kymab Limited |
Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
|
DE202014010499U1
(de)
|
2013-12-17 |
2015-10-20 |
Kymab Limited |
Targeting von humaner PCSK9 zur Cholesterinbehandlung
|
|
US9017678B1
(en)
|
2014-07-15 |
2015-04-28 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
|
US9045548B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
|
US8945560B1
(en)
|
2014-07-15 |
2015-02-03 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
US8883157B1
(en)
|
2013-12-17 |
2014-11-11 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
WO2015119906A1
(en)
|
2014-02-05 |
2015-08-13 |
Amgen Inc. |
Drug delivery system with electromagnetic field generator
|
|
EA201691320A1
(ru)
|
2014-02-14 |
2016-11-30 |
Ридженерон Фармасьютикалз, Инк. |
Способы лечения пациентов с гиперхолестеринемией, которая устойчива к терапии умеренными дозами статинов
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
CN114558129A
(zh)
*
|
2014-03-17 |
2022-05-31 |
赛诺菲生物技术公司 |
用于降低心血管风险的方法
|
|
SG11201609219QA
(en)
|
2014-05-07 |
2016-12-29 |
Amgen Inc |
Autoinjector with shock reducing elements
|
|
ES2913205T3
(es)
|
2014-05-13 |
2022-06-01 |
Bioatla Inc |
Proteínas biológicas activas condicionalmente
|
|
US20170103186A1
(en)
|
2014-06-03 |
2017-04-13 |
Amgen Inc. |
Systems and methods for supporting patient use of a drug delivery device
|
|
WO2015200438A1
(en)
*
|
2014-06-24 |
2015-12-30 |
Eleven Biotherapeutics, Inc. |
High affinity antibodies against pcsk9
|
|
US9139648B1
(en)
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
|
US9150660B1
(en)
|
2014-07-15 |
2015-10-06 |
Kymab Limited |
Precision Medicine by targeting human NAV1.8 variants for treatment of pain
|
|
DE202015009006U1
(de)
|
2014-07-15 |
2016-08-19 |
Kymab Limited |
Targeting von humaner PCSK9 zur Cholesterinbehandlung
|
|
EP3332790A1
(en)
|
2014-07-15 |
2018-06-13 |
Kymab Limited |
Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
|
|
EP4328245A3
(en)
|
2014-07-15 |
2024-06-05 |
Kymab Ltd. |
Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
|
|
KR20230074283A
(ko)
|
2014-07-16 |
2023-05-26 |
사노피 바이오테크놀로지 |
이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
|
|
AU2015289617B2
(en)
*
|
2014-07-16 |
2021-04-15 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating high cardiovascular risk patients with hypercholesterolemia
|
|
AR101262A1
(es)
|
2014-07-26 |
2016-12-07 |
Regeneron Pharma |
Plataforma de purificación para anticuerpos biespecíficos
|
|
WO2016020799A1
(en)
|
2014-08-06 |
2016-02-11 |
Rinat Neuroscience Corp. |
Methods for reducing ldl-cholesterol
|
|
JP2017523980A
(ja)
|
2014-08-06 |
2017-08-24 |
ライナット ニューロサイエンス コーポレイション |
Ｌｄｌ−コレステロールを低下させるための方法
|
|
WO2016023916A1
(en)
|
2014-08-12 |
2016-02-18 |
Kymab Limited |
Treatment of disease using ligand binding to targets of interest
|
|
US11554181B2
(en)
|
2014-09-05 |
2023-01-17 |
The University Of North Carolina At Charlotte |
Tumor specific antibody conjugates and uses therefor
|
|
EP3194441A1
(en)
|
2014-09-16 |
2017-07-26 |
Regeneron Pharmaceuticals, Inc. |
Anti-glucagon antibodies and uses thereof
|
|
EP3197492A1
(en)
|
2014-09-23 |
2017-08-02 |
Pfizer Inc |
Treatment with anti-pcsk9 antibodies
|
|
ES3056224T3
(en)
|
2014-10-14 |
2026-02-19 |
Amgen Inc |
Drug injection device with visual and audible indicators
|
|
ES2964713T3
(es)
|
2014-10-23 |
2024-04-09 |
Amgen Inc |
Reducción de la viscosidad de formulaciones farmacéuticas
|
|
WO2016071701A1
(en)
|
2014-11-07 |
2016-05-12 |
Kymab Limited |
Treatment of disease using ligand binding to targets of interest
|
|
US10799630B2
(en)
*
|
2014-12-19 |
2020-10-13 |
Amgen Inc. |
Drug delivery device with proximity sensor
|
|
MX2017005774A
(es)
|
2014-12-19 |
2017-07-28 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
|
|
EP3689394A1
(en)
|
2014-12-19 |
2020-08-05 |
Amgen Inc. |
Drug delivery device with live button or user interface field
|
|
CN114773469B
(zh)
|
2015-02-05 |
2025-12-19 |
中外制药株式会社 |
包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
|
|
CN105461809B
(zh)
*
|
2015-02-11 |
2018-10-12 |
康融东方（广东）医药有限公司 |
Pcsk9抗体、其药物组合物及其用途
|
|
US10583245B2
(en)
|
2015-02-17 |
2020-03-10 |
Amgen Inc. |
Drug delivery device with vacuum assisted securement and/or feedback
|
|
ES2905870T3
(es)
|
2015-02-27 |
2022-04-12 |
Amgen Inc |
Dispositivo de suministro de fármacos que tiene un mecanismo de protección de aguja con un umbral de resistencia ajustable al movimiento de la protección de aguja
|
|
US9139653B1
(en)
|
2015-04-30 |
2015-09-22 |
Kymab Limited |
Anti-human OX40L antibodies and methods of treatment
|
|
EP3271405A1
(en)
|
2015-03-20 |
2018-01-24 |
Aarhus Universitet |
Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders
|
|
ES3063952T3
(en)
|
2015-05-18 |
2026-04-21 |
Agensys Inc |
Antibodies that bind to axl proteins
|
|
WO2016187354A1
(en)
|
2015-05-18 |
2016-11-24 |
Agensys, Inc. |
Antibodies that bind to axl proteins
|
|
CN106084058B
(zh)
*
|
2015-07-15 |
2019-08-27 |
北京天广实生物技术股份有限公司 |
抗人pcsk9单克隆抗体
|
|
TW202440903A
(zh)
|
2015-08-04 |
2024-10-16 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法（一）
|
|
EA201890519A1
(ru)
*
|
2015-08-18 |
2018-07-31 |
Ридженерон Фармасьютикалз, Инк. |
Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов
|
|
WO2017039786A1
(en)
|
2015-09-02 |
2017-03-09 |
Amgen Inc. |
Syringe assembly adapter for a syringe
|
|
WO2017055966A1
(en)
|
2015-10-01 |
2017-04-06 |
Pfizer Inc. |
Low viscosity antibody compositions
|
|
CN106589127A
(zh)
*
|
2015-10-16 |
2017-04-26 |
钜川生物医药 |
一种pcsk9抗体及其制备方法和应用
|
|
CN105348390B
(zh)
*
|
2015-10-26 |
2018-08-28 |
北京智仁美博生物科技有限公司 |
抗人pcsk9单克隆抗体
|
|
CN106810609A
(zh)
*
|
2015-11-27 |
2017-06-09 |
苏州君盟生物医药科技有限公司 |
抗pcsk9抗体及其应用
|
|
JP7082568B2
(ja)
|
2015-12-09 |
2022-06-08 |
アムジエン・インコーポレーテツド |
信号伝達キャップ付き自動注射器
|
|
EP3394098A4
(en)
|
2015-12-25 |
2019-11-13 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE
|
|
CN107406511B
(zh)
*
|
2015-12-31 |
2021-01-19 |
江苏恒瑞医药股份有限公司 |
Pcsk9抗体、其抗原结合片段及其医药用途
|
|
WO2017120178A1
(en)
|
2016-01-06 |
2017-07-13 |
Amgen Inc. |
Auto-injector with signaling electronics
|
|
IL260931B2
(en)
*
|
2016-02-17 |
2024-09-01 |
Regeneron Pharma |
Methods of treating or preventing atherosclerosis by blocking ANGPTL3
|
|
MA43734A
(fr)
|
2016-03-03 |
2018-11-28 |
Regeneron Pharma |
Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3
|
|
WO2017160799A1
(en)
|
2016-03-15 |
2017-09-21 |
Amgen Inc. |
Reducing probability of glass breakage in drug delivery devices
|
|
US11066464B2
(en)
|
2016-03-21 |
2021-07-20 |
Kymab Limited |
Anti-malarial antibodies that bind circumsporozoite protein
|
|
WO2017163049A1
(en)
|
2016-03-21 |
2017-09-28 |
Kymab Limited |
Anti-malarial antibodies that bind circumsporozoite protein
|
|
CN107266575B
(zh)
*
|
2016-04-07 |
2021-12-24 |
天士力生物医药股份有限公司 |
前蛋白转化酶枯草溶菌素kexin 9型的结合蛋白及其应用
|
|
WO2017189089A1
(en)
|
2016-04-29 |
2017-11-02 |
Amgen Inc. |
Drug delivery device with messaging label
|
|
US11389588B2
(en)
|
2016-05-02 |
2022-07-19 |
Amgen Inc. |
Syringe adapter and guide for filling an on-body injector
|
|
MX2018013616A
(es)
|
2016-05-13 |
2019-02-21 |
Amgen Inc |
Montaje de cubierta protectora de vial.
|
|
WO2017200989A1
(en)
|
2016-05-16 |
2017-11-23 |
Amgen Inc. |
Data encryption in medical devices with limited computational capability
|
|
ES3066292T3
(en)
|
2016-06-03 |
2026-05-12 |
Amgen Inc |
Impact testing apparatuses and methods for drug delivery devices
|
|
CN107474140B
(zh)
*
|
2016-06-08 |
2022-06-03 |
常州博嘉生物医药科技有限公司 |
Pcsk9特异性的结合蛋白mv072及其应用
|
|
WO2018029474A2
(en)
|
2016-08-09 |
2018-02-15 |
Kymab Limited |
Anti-icos antibodies
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
KR102379464B1
(ko)
|
2016-06-20 |
2022-03-29 |
키맵 리미티드 |
항-pd-l1 항체
|
|
EP3478342B1
(en)
|
2016-07-01 |
2025-03-12 |
Amgen Inc. |
Drug delivery device having minimized risk of component fracture upon impact events
|
|
US11365252B2
(en)
|
2016-07-20 |
2022-06-21 |
University Of Utah Research Foundation |
CD229 CAR T cells and methods of use thereof
|
|
CN116271014A
(zh)
|
2016-08-05 |
2023-06-23 |
中外制药株式会社 |
用于预防或治疗il-8相关疾病的组合物
|
|
RU2764548C2
(ru)
|
2016-08-09 |
2022-01-18 |
Кимаб Лимитед |
Анти-icos антитела
|
|
US20190328965A1
(en)
|
2016-08-17 |
2019-10-31 |
Amgen Inc. |
Drug delivery device with placement detection
|
|
WO2018039499A1
(en)
|
2016-08-24 |
2018-03-01 |
Regeneron Pharmaceuticals, Inc. |
Host cell protein modification
|
|
WO2018054240A1
(en)
*
|
2016-09-20 |
2018-03-29 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pcsk9 antibodies
|
|
KR20190049866A
(ko)
|
2016-09-20 |
2019-05-09 |
우시 바이올로직스 아일랜드 리미티드 |
신규한 항-ｐｃｓｋ９ 항체
|
|
JP7275027B2
(ja)
|
2016-10-06 |
2023-05-17 |
アムジェン インコーポレイテッド |
粘度低下タンパク質医薬製剤
|
|
US11667697B2
(en)
|
2016-10-19 |
2023-06-06 |
Vanderbilt University |
Human orthopoxvirus antibodies and methods of use therefor
|
|
WO2018075792A1
(en)
|
2016-10-20 |
2018-04-26 |
Regeneron Pharmaceuticals, Inc. |
Methods of lowering blood glucose levels
|
|
EP3532127B1
(en)
|
2016-10-25 |
2026-04-08 |
Amgen Inc. |
On-body injector
|
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
JOP20190112A1
(ar)
|
2016-11-14 |
2019-05-14 |
Amgen Inc |
علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي
|
|
CN108239150A
(zh)
|
2016-12-24 |
2018-07-03 |
信达生物制药(苏州)有限公司 |
抗pcsk9抗体及其用途
|
|
WO2018136398A1
(en)
|
2017-01-17 |
2018-07-26 |
Amgen Inc. |
Injection devices and related methods of use and assembly
|
|
CN106749670B
(zh)
*
|
2017-01-22 |
2018-06-12 |
北京东方百泰生物科技有限公司 |
抗pcsk9单克隆抗体
|
|
CN108424457B
(zh)
*
|
2017-02-13 |
2021-06-01 |
成都金洛克锶生物技术有限公司 |
针对pcsk9抗体与检测试剂盒的制备及其用途
|
|
MX2019009755A
(es)
|
2017-02-17 |
2019-10-07 |
Amgen Inc |
Mecanismo de insercion para dispositivo de suministro de farmacos.
|
|
AU2018220538B2
(en)
|
2017-02-17 |
2023-12-14 |
Amgen Inc. |
Drug delivery device with sterile fluid flowpath and related method of assembly
|
|
JP7377596B2
(ja)
|
2017-02-22 |
2023-11-10 |
アムジエン・インコーポレーテツド |
低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
|
|
WO2018165143A1
(en)
|
2017-03-06 |
2018-09-13 |
Amgen Inc. |
Drug delivery device with activation prevention feature
|
|
KR102627069B1
(ko)
|
2017-03-07 |
2024-01-18 |
암겐 인코포레이티드 |
과압에 의한 바늘 삽입
|
|
SG11201908062QA
(en)
|
2017-03-09 |
2019-09-27 |
Amgen Inc |
Insertion mechanism for drug delivery device
|
|
MX2019011416A
(es)
|
2017-03-28 |
2019-11-01 |
Amgen Inc |
Sistema y metodo para conjunto de jeringa y vastago de embolo.
|
|
US9989519B1
(en)
*
|
2017-05-04 |
2018-06-05 |
Clayton Pharmaceuticals, LLC |
Method for determining in vitro bioequivalence of a sucralfate suspension sample to a sucralfate suspension reference listed drug (RLD)
|
|
AU2018280054B2
(en)
|
2017-06-08 |
2023-07-13 |
Amgen Inc. |
Syringe assembly for a drug delivery device and method of assembly
|
|
CA3066399A1
(en)
|
2017-06-08 |
2018-12-13 |
Amgen Inc. |
Torque driven drug delivery device
|
|
US20190031774A1
(en)
|
2017-06-09 |
2019-01-31 |
Sanofi Biotechnology |
Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
|
|
TW201904608A
(zh)
*
|
2017-06-09 |
2019-02-01 |
法商賽諾菲生物技術公司 |
藉由投予ｐｃｓｋ９抑制劑治療糖尿病患者高血脂症之方法
|
|
GB201709808D0
(en)
|
2017-06-20 |
2017-08-02 |
Kymab Ltd |
Antibodies
|
|
MA49447A
(fr)
|
2017-06-22 |
2020-04-29 |
Amgen Inc |
Réduction des impacts/chocs d'activation d'un dispositif
|
|
JP7475860B2
(ja)
|
2017-06-23 |
2024-04-30 |
アムジエン・インコーポレーテツド |
スイッチアセンブリにより起動されるキャップを含む電子薬物送達デバイス
|
|
KR20210084695A
(ko)
|
2017-07-06 |
2021-07-07 |
리제너론 파마슈티칼스 인코포레이티드 |
당단백질을 만들기 위한 세포 배양 과정
|
|
GB201710984D0
(en)
|
2017-07-07 |
2017-08-23 |
Kymab Ltd |
Cells, vertebrates, populations & methods
|
|
JP7408398B2
(ja)
|
2017-07-14 |
2024-01-05 |
アムジエン・インコーポレーテツド |
二重ねじりばねシステムを有する針挿入後退システム
|
|
JP7649105B2
(ja)
|
2017-07-21 |
2025-03-19 |
アムジエン・インコーポレーテツド |
薬物容器のためのガス透過性シーリング部材及び組立方法
|
|
EP3658206A1
(en)
|
2017-07-25 |
2020-06-03 |
Amgen Inc. |
Drug delivery device with container access system and related method of assembly
|
|
WO2019022951A1
(en)
|
2017-07-25 |
2019-01-31 |
Amgen Inc. |
DRUG DELIVERY DEVICE WITH GEAR MODULE AND ASSEMBLY METHOD THEREOF
|
|
US12318593B2
(en)
|
2017-08-09 |
2025-06-03 |
Amgen Inc. |
Hydraulic-pneumatic pressurized chamber drug delivery system
|
|
EP3668567B1
(en)
|
2017-08-18 |
2026-02-18 |
Amgen Inc. |
Wearable injector with sterile adhesive patch
|
|
US11103636B2
(en)
|
2017-08-22 |
2021-08-31 |
Amgen Inc. |
Needle insertion mechanism for drug delivery device
|
|
US12605469B2
(en)
|
2017-10-02 |
2026-04-21 |
The University Of North Carolina At Charlotte |
Tumor specific antibody conjugates and uses therefor
|
|
EP3691717B1
(en)
|
2017-10-04 |
2023-02-08 |
Amgen Inc. |
Flow adapter for drug delivery device
|
|
EP4257164A3
(en)
|
2017-10-06 |
2024-01-17 |
Amgen Inc. |
Drug delivery device with interlock assembly and related method of assembly
|
|
MA50348A
(fr)
|
2017-10-09 |
2020-08-19 |
Amgen Inc |
Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé
|
|
ES3069718T3
(en)
|
2017-11-03 |
2026-06-10 |
Amgen Inc |
System and approaches for sterilizing a drug delivery device
|
|
CA3079197A1
(en)
|
2017-11-06 |
2019-05-09 |
Amgen Inc. |
Drug delivery device with placement and flow sensing
|
|
MA50569A
(fr)
|
2017-11-06 |
2020-09-16 |
Amgen Inc |
Ensembles de remplissage-finition et procédés associés
|
|
IL319987A
(en)
|
2017-11-10 |
2025-06-01 |
Amgen Inc |
Plungers for drug delivery devices
|
|
EP4640703A3
(en)
|
2017-11-14 |
2026-04-08 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-c1s antibodies and methods of use
|
|
AU2018368340B2
(en)
|
2017-11-16 |
2024-03-07 |
Amgen Inc. |
Door latch mechanism for drug delivery device
|
|
JP7747438B2
(ja)
|
2017-11-16 |
2025-10-01 |
アムジエン・インコーポレーテツド |
失速及び終点検出を有するオートインジェクタ
|
|
WO2019122882A1
(en)
|
2017-12-19 |
2019-06-27 |
Kymab Limited |
Bispecific antibody for icos and pd-l1
|
|
GB201721338D0
(en)
|
2017-12-19 |
2018-01-31 |
Kymab Ltd |
Anti-icos Antibodies
|
|
US20190194298A1
(en)
|
2017-12-22 |
2019-06-27 |
Regeneron Pharmaceuticals, Inc. |
System and method for characterizing drug product impurities
|
|
CA3085177A1
(en)
|
2018-01-31 |
2019-08-08 |
Regeneron Pharamaceuticals, Inc. |
System and method for characterizing size and charge variant drug product impurities
|
|
WO2019152599A1
(en)
*
|
2018-01-31 |
2019-08-08 |
The Wistar Institute Of Anatomy And Biology |
Nucleic acid monoclonal antibodies targeting pcsk9 and methods of use
|
|
TW202311746A
(zh)
|
2018-02-02 |
2023-03-16 |
美商再生元醫藥公司 |
用於表徵蛋白質二聚合之系統及方法
|
|
US11957745B2
(en)
|
2018-02-22 |
2024-04-16 |
Vanderbilt University |
Human Japanese Encephalitis Virus antibodies and methods of use therefor
|
|
AU2019227531B2
(en)
|
2018-02-28 |
2025-01-30 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for identifying viral contaminants
|
|
IL277127B2
(en)
|
2018-03-06 |
2025-11-01 |
Sanofi Biotechnology |
Use of pcsk9 inhibitor for reducing cardiovascular risk
|
|
US12259355B2
(en)
|
2018-03-19 |
2025-03-25 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
US11054389B2
(en)
|
2018-03-19 |
2021-07-06 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
US12253490B2
(en)
|
2018-03-19 |
2025-03-18 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
TW202016125A
(zh)
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
|
US10835685B2
(en)
|
2018-05-30 |
2020-11-17 |
Amgen Inc. |
Thermal spring release mechanism for a drug delivery device
|
|
US11083840B2
(en)
|
2018-06-01 |
2021-08-10 |
Amgen Inc. |
Modular fluid path assemblies for drug delivery devices
|
|
FI3817770T3
(fi)
|
2018-07-02 |
2026-07-06 |
Amgen Inc |
Antigeeniä sitova anti-steap1-proteiini
|
|
US12303677B2
(en)
|
2018-07-24 |
2025-05-20 |
Amgen Inc. |
Hybrid drug delivery devices with optional grip portion and related method of preparation
|
|
CA3103682A1
(en)
|
2018-07-24 |
2020-01-30 |
Amgen Inc. |
Delivery devices for administering drugs
|
|
CN112469454B
(zh)
|
2018-07-24 |
2024-01-26 |
安进公司 |
用于施用药物的输送装置
|
|
WO2020023336A1
(en)
|
2018-07-24 |
2020-01-30 |
Amgen Inc. |
Hybrid drug delivery devices with grip portion
|
|
MA53320A
(fr)
|
2018-07-31 |
2021-11-03 |
Amgen Inc |
Ensemble de trajet de fluide pour dispositif d'administration de médicament
|
|
MX2021001431A
(es)
|
2018-08-10 |
2021-05-12 |
Chugai Pharmaceutical Co Ltd |
Molecula de union al antigeno anti grupo de diferenciacion 137 (cd137) y su uso.
|
|
MY204234A
(en)
|
2018-08-27 |
2024-08-16 |
Regeneron Pharma |
Use of raman spectroscopy in downstream purification
|
|
WO2020047067A1
(en)
|
2018-08-30 |
2020-03-05 |
Regeneron Pharmaceuticals, Inc. |
Methods for characterizing protein complexes
|
|
CN110872353B
(zh)
*
|
2018-09-03 |
2021-05-04 |
深圳华大基因科技有限公司 |
特异性结合pcsk9抗原的纳米抗体及其制备方法和应用
|
|
CA3106452A1
(en)
|
2018-09-24 |
2020-04-02 |
Amgen Inc. |
Interventional dosing systems and methods
|
|
US12042642B2
(en)
|
2018-09-28 |
2024-07-23 |
Amgen Inc. |
Muscle wire escapement activation assembly for a drug delivery device
|
|
WO2020072577A1
(en)
|
2018-10-02 |
2020-04-09 |
Amgen Inc. |
Injection systems for drug delivery with internal force transmission
|
|
JP7547325B2
(ja)
|
2018-10-05 |
2024-09-09 |
アムジエン・インコーポレーテツド |
投薬量インジケータを有する薬物送達デバイス
|
|
MA53913A
(fr)
|
2018-10-15 |
2022-01-19 |
Amgen Inc |
Procédé d'assemblage de plate-forme pour dispositif d'administration de médicament
|
|
JP7719714B2
(ja)
|
2018-10-15 |
2025-08-06 |
アムジエン・インコーポレーテツド |
ダンピング機構を有する薬物送達装置
|
|
SG11202104120VA
(en)
*
|
2018-10-31 |
2021-05-28 |
Delinia Inc |
Multivalent regulatory t cell modulators
|
|
CN111110841A
(zh)
*
|
2018-10-31 |
2020-05-08 |
上海君实生物医药科技股份有限公司 |
含有抗pcsk9抗体的稳定制剂
|
|
TWI831847B
(zh)
|
2018-11-01 |
2024-02-11 |
美商安進公司 |
部分針頭縮回之藥物遞送裝置及其操作方法
|
|
WO2020091956A1
(en)
|
2018-11-01 |
2020-05-07 |
Amgen Inc. |
Drug delivery devices with partial drug delivery member retraction
|
|
MA54057A
(fr)
|
2018-11-01 |
2022-02-09 |
Amgen Inc |
Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament
|
|
GB201820687D0
(en)
|
2018-12-19 |
2019-01-30 |
Kymab Ltd |
Antagonists
|
|
JP2022517720A
(ja)
|
2019-01-16 |
2022-03-10 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ジスルフィド結合を特徴付けるための方法
|
|
CN109734813B
(zh)
*
|
2019-01-28 |
2022-06-17 |
广东昭泰体内生物医药科技有限公司 |
一种嵌合抗原受体及其应用
|
|
EP3958934B1
(en)
|
2019-04-24 |
2025-04-09 |
Amgen Inc. |
Syringe sterilization verification assemblies and methods
|
|
JP7541534B2
(ja)
|
2019-05-13 |
2024-08-28 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
改善された競合的リガンド結合アッセイ
|
|
CA3137649A1
(en)
|
2019-05-15 |
2020-11-19 |
Chugai Seiyaku Kabushiki Kaisha |
An antigen-binding molecule, a pharmaceutical composition, and a method
|
|
EP3969620B1
(en)
|
2019-05-17 |
2025-06-25 |
Regeneron Pharmaceuticals, Inc. |
Genome-based methods for reducing cardiovascular risk
|
|
US12559551B2
(en)
|
2019-05-24 |
2026-02-24 |
Regeneron Pharmaceuticals, Inc. |
Stabilized formulations containing anti-ANGPTL3 antibodies
|
|
US20220273887A1
(en)
|
2019-08-23 |
2022-09-01 |
Amgen Inc. |
Drug delivery device with configurable needle shield engagement components and related methods
|
|
WO2021058597A1
(en)
|
2019-09-24 |
2021-04-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of determining whether a subject is at risk of developing arterial plaques
|
|
KR20260058863A
(ko)
|
2019-09-24 |
2026-04-29 |
리제너론 파아마슈티컬스, 인크. |
크로마토그래피의 사용 및 재생을 위한 시스템 및 방법
|
|
US12297451B1
(en)
|
2019-10-25 |
2025-05-13 |
Regeneron Pharmaceuticals, Inc. |
Cell culture medium
|
|
US11730793B2
(en)
|
2019-11-25 |
2023-08-22 |
Regeneron Pharmaceuticals, Inc. |
Sustained release formulations using non-aqueous emulsions
|
|
JP2023506732A
(ja)
|
2019-12-10 |
2023-02-20 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ホモ接合型家族性高コレステロール血症を処置するためのｐｃｓｋ９阻害剤の使用
|
|
CA3165060C
(en)
|
2020-01-21 |
2023-06-20 |
Yiming Zhao |
Deglycosylation methods for electrophoresis of glycosylated proteins
|
|
JP7765457B2
(ja)
*
|
2020-08-06 |
2025-11-06 |
ステレクシス セラピューティクス，エルエルシー |
Ｉｌ－８抗体及びその使用方法
|
|
KR20230058094A
(ko)
|
2020-08-31 |
2023-05-02 |
리제너론 파아마슈티컬스, 인크. |
세포 배양 성능을 개선하고 아스파라긴 서열 변이체를 완화하기 위한 아스파라긴 공급 전략
|
|
EP4251128A1
(en)
|
2020-11-25 |
2023-10-04 |
Regeneron Pharmaceuticals, Inc. |
Sustained release formulations using non-aqueous membrane emulsification
|
|
IL303675A
(en)
|
2020-12-17 |
2023-08-01 |
Regeneron Pharma |
Production of protein thermal microgels
|
|
MX2023008527A
(es)
|
2021-01-20 |
2023-07-28 |
Regeneron Pharma |
Metodos para mejorar el valor proteico en cultivo celular.
|
|
TW202246325A
(zh)
|
2021-03-03 |
2022-12-01 |
美商再生元醫藥公司 |
用於定量及修飾蛋白質黏度之系統及方法
|
|
EP4315344A1
(en)
|
2021-03-26 |
2024-02-07 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for developing mixing protocols
|
|
CA3219336A1
(en)
|
2021-05-18 |
2022-11-24 |
Kymab Limited |
Uses of anti-icos antibodies
|
|
BR112023024278A2
(pt)
|
2021-05-21 |
2024-01-30 |
Amgen Inc |
Método de otimizar uma receita de enchimento para um recipiente de fármacos
|
|
AU2022286340A1
(en)
|
2021-06-01 |
2024-01-04 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
GB202107994D0
(en)
|
2021-06-04 |
2021-07-21 |
Kymab Ltd |
Treatment of cancer
|
|
AU2022307659A1
(en)
|
2021-07-05 |
2024-01-25 |
Regeneron Pharmaceuticals, Inc. |
Utilization of antibodies to shape antibody responses to an antigen
|
|
MX2024001877A
(es)
|
2021-08-10 |
2024-02-28 |
Kymab Ltd |
Tratamiento de dermatitis atopica.
|
|
AR127006A1
(es)
|
2021-09-08 |
2023-12-06 |
Regeneron Pharma |
UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc
|
|
AU2022348521A1
(en)
|
2021-09-20 |
2024-04-04 |
Regeneron Pharmaceuticals, Inc. |
Methods of controlling antibody heterogeneity
|
|
EP4413359A1
(en)
|
2021-10-07 |
2024-08-14 |
Regeneron Pharmaceuticals, Inc. |
Ph meter calibration and correction
|
|
EP4413364A2
(en)
|
2021-10-07 |
2024-08-14 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods of ph modeling and control
|
|
WO2023076340A1
(en)
|
2021-10-26 |
2023-05-04 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
|
|
EP4493921A1
(en)
|
2022-03-18 |
2025-01-22 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for analyzing polypeptide variants
|
|
EP4525991A1
(en)
|
2022-05-18 |
2025-03-26 |
Kymab Limited |
Uses of anti-icos antibodies
|
|
WO2024040020A1
(en)
|
2022-08-15 |
2024-02-22 |
Absci Corporation |
Quantitative affinity activity specific cell enrichment
|
|
WO2024130165A1
(en)
|
2022-12-16 |
2024-06-20 |
Regeneron Pharmaceuticals, Inc. |
Angptl3 inhibitors for triglyceride reduction in multifactorial chylomicronemia syndrome
|
|
EP4634659A1
(en)
|
2022-12-16 |
2025-10-22 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for assessing chromatographic column integrity
|
|
US20240248097A1
(en)
|
2023-01-25 |
2024-07-25 |
Regeneron Pharmaceuticals, Inc. |
Mass spectrometry-based characterization of antibodies co-expressed in vivo
|
|
US20240245779A1
(en)
|
2023-01-25 |
2024-07-25 |
Regeneron Pharmaceuticals, Inc. |
Methods of modeling liquid protein composition stability
|
|
TW202445138A
(zh)
|
2023-02-01 |
2024-11-16 |
美商再生元醫藥公司 |
用於生物巨分子分析之具質譜法的不對稱流場流分離
|
|
EP4669963A2
(en)
|
2023-02-22 |
2025-12-31 |
Regeneron Pharmaceuticals, Inc. |
SYSTEM FITNESS PARAMETERS AND COLUMN AGING
|
|
JP2026514305A
(ja)
|
2023-05-01 |
2026-05-08 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
フェノールまたはベンジルアルコールを使用した複数回投与抗体医薬品
|
|
WO2024240848A1
(en)
*
|
2023-05-23 |
2024-11-28 |
Jlp Health Gmbh |
Ldlr derived polypeptides for anti-viral uses
|
|
EP4467563A1
(en)
*
|
2023-05-23 |
2024-11-27 |
JLP Health GmbH |
Ldlr derived polypeptides for anti-viral uses
|
|
US20250086164A1
(en)
|
2023-09-08 |
2025-03-13 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for assessing chromatographic column integrity
|
|
EP4780828A2
(en)
|
2023-09-18 |
2026-07-29 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for developing chromatography protocols
|
|
US20250109905A1
(en)
|
2023-09-29 |
2025-04-03 |
Regeneron Pharmaceuticals, Inc. |
Lyophilization using controlled nucleation
|
|
CN122138969A
(zh)
|
2023-10-18 |
2026-06-02 |
瑞泽恩制药公司 |
从过程中上游细胞培养物材料中快速纯化单克隆抗体
|
|
AU2024373307A1
(en)
|
2023-11-02 |
2026-05-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing lipase activity using stress
|
|
WO2025144700A1
(en)
|
2023-12-27 |
2025-07-03 |
Absci Corporation |
Nanobody library screening using bacterial surface display
|
|
WO2025166281A1
(en)
|
2024-02-01 |
2025-08-07 |
Regeneron Pharmaceuticals, Inc. |
Platform for charge-detection mass spectrometry analysis of aavs
|
|
TW202600593A
(zh)
|
2024-02-16 |
2026-01-01 |
美商再生元醫藥公司 |
製造濃縮配製包括蛋白質之藥品物質之方法，以及該方法製造之濃縮配製之藥品物質
|
|
TW202602489A
(zh)
|
2024-03-15 |
2026-01-16 |
美商再生元醫藥公司 |
作為經穩定的蛋白質調配物之賦形劑的聚山梨醇酯及聚氧乙烯山梨糖醇酐
|
|
WO2025259840A1
(en)
|
2024-06-13 |
2025-12-18 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for scaled chromatography
|
|
WO2026025028A1
(en)
|
2024-07-26 |
2026-01-29 |
Regeneron Pharmaceuticals, Inc. |
Methods of making ultra-high concentrated protein formulations using lyophilization
|
|
WO2026030152A1
(en)
|
2024-07-29 |
2026-02-05 |
Amgen Inc. |
System and method for assessing transferability of a fill recipe
|
|
WO2026060350A1
(en)
|
2024-09-13 |
2026-03-19 |
Regeneron Pharmaceuticals, Inc. |
Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods
|
|
WO2026076201A2
(en)
|
2024-10-03 |
2026-04-09 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools
|
|
WO2026080597A1
(en)
|
2024-10-08 |
2026-04-16 |
Regeneron Pharmaceuticals, Inc. |
Sustained delivery of biologics and non-aqueous manufacture of same
|
|
WO2026112457A2
(en)
|
2024-11-21 |
2026-05-28 |
Regeneron Pharmaceuticals, Inc. |
Heterodimeric antigen-binding molecules that bind to viral particles and uses thereof
|
|
WO2026136650A1
(en)
|
2024-12-20 |
2026-06-25 |
Regeneron Pharmaceuticals, Inc. |
Fixed seed train schedule for improved protein production
|